Share your videos with the world

Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years. Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government. AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60. To view the multimedia release go to: http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/

Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today. One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma. To view the multimedia release go to: http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/

HP today unveiled the world’s first commercially available HP Moonshot system, delivering compelling new infrastructure economics by using up to 89 percent less energy, 80 percent less space and costing 77 percent less, compared to traditional servers. Today’s mega data centers are nearing a breaking point where further growth is restricted due to the current economics of traditional infrastructure. HP Moonshot servers are a first step organizations can take to address these constraints. To view Multimedia News Release, go to http://www.multivu.com/mnr/60973-hp-launches-new-class-of-server-for-social-mobile-cloud-and-big-data